VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.)’ SynCon(TM) Pandemic Flu Vaccine Protects Against A Lethal Challenge of Live Virus in Pre-Clinical Animal Models

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals’ SynCon™ (Synthetic Consensus) pandemic flu DNA vaccines (VGX-3400) provided protection against a lethal challenge of live H5N1 viruses, according to data presented today by Dr. Ruxandra Draghia-Akli at the MVAF 2007-Modern Vaccines/Adjuvants Formulation Conference in Dublin, Ireland.